Design Therapeutics (DSGN) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Oppenheimer | Maintained | Outperform | $21.00 from $18.00 | May 4, 2026 |
| Jefferies | Initiated Coverage | Buy | $15.00 | Mar 16, 2026 |
| RBC Capital | Maintained | Outperform | $14.00 from $13.00 | Mar 10, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $18.00 | Jan 7, 2026 |
| Leerink Partners | Upgraded | Market Perform → Outperform | $14.00 from $7.00 | Dec 3, 2025 |
| RBC Capital | Upgraded | Sector Perform → Outperform | $13.00 from $6.00 | Nov 20, 2025 |
| RBC Capital | Maintained | Sector Perform | $6.00 from $5.00 | Nov 6, 2025 |
| RBC Capital | Maintained | Sector Perform | $4.00 | Aug 6, 2024 |
| Piper Sandler | Upgraded | Neutral → Overweight | $12.00 from $6.00 | May 7, 2024 |
| Wedbush | Maintained | Neutral | $5.00 | Mar 20, 2024 |
| RBC Capital | Maintained | Sector Perform | $4.00 | Mar 20, 2024 |
| RBC Capital | Maintained | Sector Perform | $4.00 from $7.00 | Nov 14, 2023 |
| Wedbush | Downgraded | Outperform → Neutral | $6.00 | Aug 15, 2023 |
| SVB Leerink | Downgraded | Outperform → Market Perform | $6.00 | Aug 15, 2023 |
| RBC Capital | Downgraded | Outperform → Sector Perform | $7.00 from $23.00 | Aug 15, 2023 |
| Wedbush | Maintained | Outperform | $19.00 from $20.00 | May 10, 2023 |
| RBC Capital | Maintained | Outperform | $23.00 from $24.00 | May 10, 2023 |
| Goldman Sachs | Upgraded | Sell → Neutral | — | May 4, 2023 |
Frequently asked questions
Is DSGN a buy, sell, or hold?
Analysts covering Design Therapeutics currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on DSGN?
On May 4, 2026, Oppenheimer maintained Design Therapeutics at Outperform with a price target of $21.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.